|Bid||5.93 x 4000|
|Ask||5.94 x 2200|
|Day's Range||5.67 - 5.94|
|52 Week Range||2.93 - 17.37|
|Beta (5Y Monthly)||2.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
During Q2, Clovis Oncology's (NASDAQ: CLVS) reported sales totaled $39.89 million. Despite a 0.78% in earnings, the company posted a loss of $82.65 million. In Q1, Clovis Oncology brought in $42.56 million in sales but lost $82.01 million in earnings.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Clovis Oncology posted an ROCE of 0.85%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on CLVSReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.For Clovis Oncology, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.Q2 Earnings Insight Clovis Oncology reported Q2 earnings per share at $-1.11/share, which did not meet analyst predictions of $-1.04/share.See more from Benzinga * Return On Capital Employed Overview: Clovis Oncology(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.